Jonathan E. Freeman - 05 Feb 2026 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role
Director
Signature
/s/ Lisa C. Carson, Attorney-in-Fact
Issuer symbol
PHIO
Transactions as of
05 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 08:00:21 UTC
Previous filing
15 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Freeman Jonathan E Director C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA /s/ Lisa C. Carson, Attorney-in-Fact 06 Feb 2026 0001708133

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHIO Common Stock, $.0001 par value Award $0 +16,600 +103% $0.000000 32,655 05 Feb 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2 Includes shares of common stock underlying unvested restricted stock units.
F3 The number of reported securities has been adjusted to reflect prior reverse stock splits.